Download PDF
Nuklearmedizin 2009; 48(05): N45-N46
DOI: 10.1055/s-0037-1621115
Case report
Schattauer GmbH

Bone metastasis of a breast cancer detected by 3'-deoxy-3'-18F-fluorothymidine PET/CT

A. Cochet
1   Nuclear Medicine Department, Centre Georges-François Leclerc, Dijon, France
,
A. Berriolo-Riedinger
1   Nuclear Medicine Department, Centre Georges-François Leclerc, Dijon, France
,
S. Girault
2   Nuclear Medicine Department, Centre Paul Papin, Angers, France
,
C. Rousseau
3   Nuclear Medicine Department, Centre René Gauducheau, Saint-Herblain, France
,
F. Brunotte
1   Nuclear Medicine Department, Centre Georges-François Leclerc, Dijon, France
,
O. Couturier
4   Nuclear Medicine Department, Inserm U646, Angers, France
› Author Affiliations
Further Information

Publication History

Received: 20 December 2008

accepted in revised form: 26 June 2009

Publication Date:
20 January 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Uematsu T, Yuen S, Yukisawa S. et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005; 184: 1266-1273.
    CrossrefPubMedGoogle Scholar
  • 2 Pio BS, Park CK, Pietras R. et al. Usefulness of 3'-18F-fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006; 8: 36-42.
    CrossrefPubMedGoogle Scholar
  • 3 Kenny L, Coombes RC, Vigushin DM. et al. Imaging early changes in proliferation at 1 week post chemotherapy : a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007; 34: 1339-1347.
    CrossrefPubMedGoogle Scholar
  • 4 Dittmann H, Dohmen BM, Paulsen F. et al. [18F]FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging 2003; 30: 1407-1412.
    CrossrefPubMedGoogle Scholar